Backorders and complaints over low supply started moderating in the second week of May, the drugmaker said, after it began ramping up production of the antiviral drug last month.
Future supply of the drug will also depend on the course of the pandemic in India but "manufacturing is no longer the bottleneck," Upadhye said.
"Destructive tax competition will only end when enough major economies stop undercutting one another and agree to a global minimum tax," US Treasury Secretary Janet Yellen said.